Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Emerging Market in Medicare Part D and Sponsor Compliance Strategies A Presentation to the Pharmaceutical Compliance Congress November 8, 2005 John.

Similar presentations

Presentation on theme: "The Emerging Market in Medicare Part D and Sponsor Compliance Strategies A Presentation to the Pharmaceutical Compliance Congress November 8, 2005 John."— Presentation transcript:

1 The Emerging Market in Medicare Part D and Sponsor Compliance Strategies A Presentation to the Pharmaceutical Compliance Congress November 8, 2005 John Gorman President/CEO Gorman Health Group, LLC 2176 Wisconsin Avenue, NW Washington, DC (202) Fax: (202)

2 Todays Agenda The Emerging Market in Medicare Part D - Medicare Advantage: Local and Regional Outlook - Prescription Drug Plans (PDPs) - Employers and Retiree Groups Medicare Fraud, Waste and Abuse (FWA) Issues and Sanctions Compliance and FWA Elements Medicare Prescription Drug Integrity Contractors (MEDICs) and Their Role Part D Plan Sponsor FWA Exposure PBM Integrity Subcontractor Oversight Keys to Minimizing Exposure Conclusions

3 Beneficiaries Will Have Several Coverage Options New Medicare Part D Beneficiaries Will Have Several Coverage Options Must offer benefits equivalent to standard coverage to receive subsidy Medicare Options Other Options Prescription Drug-only Plan (PDP)/ FFS Add-On Medicare Advantage PPO Option Medicare Advantage HMO Option Qualified Employer Plan Medicare Advantage PPO Option Special Needs Plan (SNP) Option Must offer benefits equivalent to standard coverage Regional Options Blended benchmark Stabilization fund Risk Corridors Local (county- based) Options Must offer benefits equivalent to standard coverage on at least one plan in portfolio Limited Risk or Fallback Drug- Only Plan If insufficient number of PDPs or PPOs emerge in the market

4 Medicare Risk Contracts 1985 to 2005 Source: CMS, October Note: 570 PDPs will launch on January 1, 2006.

5 SNPs Convergence of Health Policy Factors Create Opportunities for SNPs Medicaid Reform Risk Adjustment Part D Auto-Enroll of Duals Lock-In Exemptions

6 Regional PPO Sponsors and Revenue vs. Cost Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Region % Source: GHG analysis adapted from CMS 2005 MA Payment Rates and 99% FFS Cost Files, January WLP HUM UHC SIE NPA AET BSC HNT HUM WLP HUM

7 Competitive Landscape for PDPs

8 Impact of Dual Assignments on PDPs Source: Lehman Brothers and GHG Analysis, September 2005.

9 PDPs to Watch ApplicantPartnerScope AetnaAetna PMAll 34 regions MedcoNAAll 34 regions HealthNetNA6 regions WellPointWellPoint PMAll 34 regions Universal American Financial Corp. PharmaCare32 regions United HealthcareWalgreens HI All 34 regions (AARP endorsement) SierraNA8 regions WellCareWalgreens HIAll 34 regions Heartland Alliance (6 BCBS plans) Prime TherapeuticsUpper Midwest Region CIGNA/NationsHealthCIGNA PMAll 34 regions PacifiCarePrescription SolutionsAll 34 regions HumanaArgus31 regions CoventryRite AidAll 34 regions Source: company reports

10 Part D Final Benchmarks for 2006 Actual (8/9/05) Expected (3/2005) Difference Base monthly beneficiary premium $32.20$ % Average Part D Benchmark (PMPM) $94.08$ %

11 Summary The minimum number of plans participating in any of the regions is 11 (Region 34, Alaska). The maximum amount of plans participating is 20 plans (NY, TX, OR/WA). In 37 states 100% of Medicare eligibles will have access to a PPO plan. The number of auto-assigned beneficiaries per organization in a given region will range from as low as 2,000 to the 6 plans in Alaska to as high as 133,000 individuals in the 7 plans in California.

12 Part D Projections: 2006 GHG expects in 2006: $112B in revenues generated for private plans (up from $51B in 2005) – 38% ($42B) through PDPs 900,000 new beneficiaries in MA products (5.8M in 2005) 14.3M in PDPs (including duals and low- income) Therefore, over 21M beneficiaries in some form of managed care in 2006

13 Strategies Employers Are Likely to Pursue in 2006

14 Retiree Health Benefits: Two Choices for Employers For 2006, Expect Most Employers to Choose RDS but some may prefer Part D Actuarial Equivalence - employer plan may not qualify for the RDS Part D offers higher subsidies, especially for employers with low utilization Tax status - governmental entities or nonprofits do not realize the tax benefits of RDS Retirees already in MA plans LIS – may be better off in Part D Administrative – Part D plans handle administration and financial risk

15 Retiree Health Benefits: Two Choices for Employers For 2007 and Beyond, expect a shift to Part D Market will be known Financial benefits of Part D will be clearer Time to submit Part D applications Fewer employers will qualify for the RDS, e.g. percent of plans meeting cap

16 Employer Options for Retiree Drug Coverage

17 Impacts of Retiree Drug Coverage Options EmployersRetirees RDSAdministrative Simplicity Compliance Risk No change Part DSubsidies could be higher than RDS Low income retirees could benefit Part D-EndorseMedicare primary – employer contribution small Choice May be less coverage Part D–Stand alone wrap COB issues Different providers and formularies Same coverage – may need to pay out of pocket and seek reimbursement Part D– Integrated Wrap One stop shopping Part D plan assumes risk New plan for drug coverage Part D–Direct contract Eliminate middleman Financial and compliance risk Seamless

18 Impact of Likely Employer Strategies % of retirees likely to be in plans that continue drug benefit coverage and accept the 28% subsidy 6% of retirees likely to be in plans that supplement Medicare drug coverage 4% of retirees likely to be in plans that discontinue drug coverage 13% of retirees in plans that do not yet know their strategy or had a different strategy Source: Kaiser/Hewitt Survey, December 2004.

19 Privatization of the Drug Market Private Health Insurance 48% Consumer Out-of-Pocket 30% Medicaid, Other Public 22% Consumer Out-of-Pocket 18% Private Health Insurance 70% Medicaid, Other Public 12% Total U.S. Drug Spending Before Medicare Drug Benefit After Medicare Drug Benefit Sources: CMS, National Health Spending, 2002; and CBO, Issues in Designing a Prescription Drug Benefit for Medicare, Oct, 2002.

20 Compliance Strategies for Part D Sponsors

21 Government Oversight Structures CMS – Part C & D Monitoring Programs year on-site, regularly - scheduled audit cycle, depending on risk assessment for MA plans (3 years for PD plan) - Focused/targeted desk and on-site audits, depending on risk assessment MEDICS Monitor and evaluate data and trends to identify potential fraud, abuse, and waste in the Medicare Part D Program. - Receive reports from contractors and beneficiaries - Develop and refer cases to the appropriate Law Enforcement (LE) Agency or to CMS for administrative action as necessary Inspector General - Civil Money penalties - Exclusion Department of Justice - Civil and Criminal Prosecution

22 Medicare Part D Compliance Plan Required Elements 7 Required Elements of a Part D Compliance Program Written policies, procedures and standards of conduct regarding compliance with all applicable Federal and State standards Compliance Officer and Committee accountable to senior management Effective training programs for employees, contractors, agents and directors Effective lines of communication Enforcement through well-publicized disciplinary guidelines Effective internal monitoring and auditing Prompt response to detected offenses (e.g. payment or delivery of drugs) and development of corrective action initiatives (e.g. repayment of overpayments and disciplinary actions) Comprehensive Fraud and Abuse Program Detect, correct, and prevent fraud, waste, and abuse Voluntary self-reporting of potential fraud or misconduct Separate plan or integrate with the other 7 compliance plan elements

23 Medicare Compliance and FWA Risks Standard Part C Compliance Tests that will Apply to Part D Sponsors: Fails to provide medically necessary services, if adverse effect Imposes excess charges on enrollees Discourages enrollment due to health status Misrepresents or Falsifies information Employs or contracts with excluded individuals and entities Substantially fails to carry out the contract, inefficient administration of the contract, or no longer substantially meets the contract requirements

24 Medicare Compliance and FWA Risks Administrative Sanctions - Contract Termination - Intermediate Sanctions (Suspension of enrollment and payment) Exclusion from all Federal Programs Civil Monetary Penalties - $25,000 for each failure to provide medically necessary services, health screening or falsification of information to the Secretary - $25,000 for each determination of failure to carry out the contract if adverse effect

25 Medicare Compliance and FWA Risks Criminal Penalties (felony conviction and up to 5 year imprisonment) Knowing and willful false statement or misrepresentation of fact in application for benefit or payment under a federal health care program Knowing and willful kickback, bribe or rebate to inappropriately secure federal funds False Claims (Whistleblowers) Act Signature acknowledging that information is being submitted for purposes of obtaining Federal funds triggers the FCA FCA prohibits false or fraudulent claims Treble damages and up to $11,000 per claim Whistleblowers receive up to 30% of the recovery Liability extends to those who submit the false claim and those who cause the submission of the false claim Intent to defraud is not required – mistake or negligence with system wide effects sufficient

26 MEDIC Part D - Data Analysis Utilization Management Medication Adherence and Persistence Quality Assurance Performance Measures Coverage Determination Long Term Care (LTC) - Pharmacy Access Complaint Tracking

27 CMS Data Collection – Management Information Integrated Repository Performance Assessment Data mining and standard reports will be used to inform CMS of Plans performance under Part D Standard Required Reports PDE data (claims data) Eligibility data Complaint data (CTM) Plan-reported data (HPMS) Plan-finder data

28 MEDICS Role In CMS Compliance and FWA Review & Audit – CMS Defense against the Mississippi River of Dollars IDIQ Contract (Indefinite Delivery – Indefinite Quantity Solicitation) Of the 21 Examples of General Fraud, Waste and Abuse in the MEDIC Statement of Work, 15 were targeted toward PBM or pharmacy related issues and business practices – 6 were Beneficiary fraud issues - PBMs and Part D Sponsors will be at risk for the acts of their downstream pharmacy contractors for false claim submission Of the 12 Examples of potential Financial Fraud, all 12 will impact PBMs - Effective cost allocation systems critical for administrative services - Rebate contracts will be under scrutiny

29 General Fraud and Abuse Issues Misrepresenting the enrollment, encounter, or prescription drug event data Improper reporting of prescriptions dispensed to maximize payments. Billing for services not furnished and/or drugs not provided. Billing that appears to be a deliberate application for duplicate payment Soliciting, offering, or receiving a kickback, bribe, or rebate Billing based on gang visits Billing non-covered prescriptions as covered items Billing under Part A or Part B, and also under Part D

30 General Fraud and Abuse Issues (Continued) Dispensing without a prescription Billing for recycled prescription drugs Submitting false Medicare claims Receiving duplicative co-pays or premiums from beneficiaries Billing for brand when generics are dispensed Altering scripts or data to obtain a higher payment amount Misrepresentations of dates, descriptions of prescriptions or services

31 MEDICS Role In CMS Compliance and FWA Review & Audit – CMS Defense against the Mississippi River of Dollars 8 MEDICs selected: NDCHealth Delmarva Foundation for Medical Care Electronic Data Systems (EDS) IntegriGuard Livanta Maximus Federal Services Perot Systems Government Services Science Applications International Corporation (SAIC)

32 MEDICS Role In CMS Compliance and FWA Review & Audit – CMS Defense against the Mississippi River of Dollars MEDICs Responsibilities include: Review Part D and RDS plan compliance data to detect fraud Review bids and FWA components of compliance plans Coordinate with law officials Conduct investigations, including audits of PDPs and sub- contractors MEDICs will annually audit at least 1/3 of PDP and MA plans Risk Based Audit Strategy – conduct more investigation and analysis with unusual billing patterns

33 MEDICS Role In CMS Compliance and FWA Review & Audit – CMS Defense against the Mississippi River of Dollars MEDICs Responsibilities (contd) Review improper enrollment and eligibility Review improper marketing and distribution Audit RDS sponsors, including RDS eligibility and claims review Conduct Part D, MA and RDS complaint investigations

34 MEDIC Audit Target Drivers Near Term: - Beneficiary Complaint Data (e.g. sales misrepresentation) - Past PBM issues identified in legal proceedings will be focus of audit - Areas where there are questions of transparency - Eligibility and Claims Data audits for Retiree Drug Subsidy Longer Term: - PDE data and comparisons with other Medicare Claims Data - Whistleblowers - Routine on-site audit reviews (P & T, FWA implementation etc.)

35 MEDIC Audit Target Drivers The Good News on MEDICS - All New to Medicare Part D - First Timers or with Some Experience - Data will take time to gather But get it right from the start

36 General Keys To Avoiding the Inspector General Listen to the Noise surrounding Part D - Identify potential CMS or Congressional hot button issues and address them – e.g. Beneficiaries can find appropriate education materials Avoid Misinterpretation of Part D Requirements – Ever watchful for changing CMS regulation or guidance Pay attention to past industry criticisms, jibes and legal proceedings and develop policies and oversight in the areas of concern Assess and audit current business and operational practices at a granular level to identify areas of exposure or lack of controls - Require process by process policy review and standards and FWA monitoring requirements Ensure documentation of procedures and process descriptions Ensure diligence in systems configuration auditing to catch errors prior to submission

37 Further Keys To Avoiding the Inspector General Implement granular financial auditing, process controls, monitoring Use central tracking system for all internal FWA control reporting Establish routine monitoring and audits of operations - Review appropriate staffing for internal auditors - Review staffing, scope and frequency of pharmacy audit Monitor Enrollee grievance and appeals activity - Enrollees who dont get things trigger problems - Early Warning System Develop corrective action plans Establish processes for self-reporting of potential FWA - Encourage / Incent Internal FWA issue identification & referrals - Make the FWA department well known Thorough training at all levels

38 Part D Compliance & FWA Exposure - Overview 5 Critical Areas for a Part D Plan Sponsor - Part D Specific Requirements – Audits in areas such as TrOOP, Copay application, COB, PDE data, formulary changes, etc. - PBM Integrity – Major PBMs are high profile candidates for FWA audits in areas like pricing, rebates, benefit adjudication, etc. - Subcontractor Oversight and FWA Issues – Retail pharmacies, LTC pharmacies (Part A/D), enrollment contractor etc. - Beneficiary-Prescriber FWA Identification and Management – Identifying and managing these issues - Sales Misrepresentation and Fraud- a new issue for PDP Sponsors and a common CMS target and reason for sanction based on complaints

39 Part D Compliance & FWA Exposure - Overview For Each 5 Critical Areas, Part D Plan Sponsors should develop: Tracking and Reporting mechanisms to report to CMS and the MEDICS Audit and Monitoring Strategies with designated Resources - On-Site or Desk Audit - Conducted by the Part D plan sponsor, the PBM, or Audit organization Corrective Action strategies Training Self-reporting of suspected FWA

40 Part D Specific Requirements - FWA Touch Points Enrollment Accuracy – LIS, Duals, Late Penalty, Proper Effective Dates Beneficiary Billing Accuracy Direct bill vs. SSA Proper Refunds to Beneficiaries, Charities Premiums, cost sharing and accounting Reconciliations General Administrative Cost Allocations Specific program cost allocations, e.g. MTMP

41 Part D Specific Requirements - FWA Touch Points (Continued) Formulary development and beneficiary notification of formulary changes Generic vs. Brand Appeals and Grievances Monitoring, Feedback Loops and Disciplinary Programs COB data collection, working with the COB Facilitator

42 Part D Specific Requirements - FWA Touch Points (Continued) TrOOP accumulation Includes only eligible cost sharing, e.g. includes beneficiary payments and excludes group health plan payments Properly includes all 6 payment fields: - Patient Pay Amount - Other TrOOP - Low Income Cost Sharing Subsidy Amount (LICS) - Covered D Plan Paid Amount (CPP) - Non-covered Plan Paid Amount, (NPP) - Patient Liability Reduction due to Other Payer Amount (PLRO)

43 Part D Specific Requirements - FWA Touch Points (Continued) PDE (Prescription Drug Event) data accuracy 100% claims data necessary to calculate risk adjustment, LICS, reinsurance, and risk corridor payments Proper reflection of costs to be included or excluded in each of the 4 payment calculations, e.g. - Only Part D drugs covered under the specific plan - Risk corridor calculations must exclude administrative costs, patient pay amounts, induced utilization, rebates, reinsurance subsidy - Reinsurance calculations must reflect full TrOOP accounting - All calculations must properly account for all rebates, discounts, and other price concessions

44 PBM Integrity FWA Touch Points Pharmacy Contracting, Term Application and Disclosure Proper Benefit Set Up And Adjudication at POS Eligibility Accuracy and benefit plan assignment Drug Pricing – AWP, MAC etc. Claims Edit & Processing Accuracy (e.g. Part A, B and excluded drugs)

45 PBM Integrity FWA Touch Points (Continued) Mail Order Prescription Fills Rebate Accounting and Pass – Through Member level detail and transparency E-Prescribing

46 Subcontractor Oversight Retail Pharmacy Monitor dispensing activity of specifically identified retail pharmacies Retail audit by PBM or Audit organization to identify outlier pharmacies Desk audit on all outlier claims to determine: - Appropriateness of RX dispensed - Correct quantity and strength of medication - Correct administration of benefit design and trend management programs - Instances of potential fraud and abuse On Site audit of pharmacies that continue outlier dispensing performance

47 Subcontractor Oversight Retail Pharmacy (continued) Automated reporting editing systems can include the following triggers: - Dispensing volume of high profile medications (e.g. controlled substances, medications targeted for re- sale or addicted medications) - Significant number or percent of U & C claims - Multiple instances of reversed or altered claims - Multiple pharmacy overrides to excluded or Prior Authorized medications - Excessive units per day dispensing - High dollar medications

48 Subcontractor Oversight Retail Pharmacy (continued) Individual Pharmacist Audit - Based on conclusions from the on-site audit, more focused audits of individual pharmacists may be warranted to review: - Potential cases of trafficking - Potential cases of fraud and abuse Retail Pharmacy audits also may include review of: - Disclosure of low cost generic - Non-submission of zero-balance claims - COB Audits – Duplicate Billing

49 Subcontractor Oversight LTC Pharmacies - Example: Determining whether LTC pharmacy filed claims should be part of a Part A Skilled Nursing Benefit - Proper destruction or return of drugs Enrollment and Premium Billing Subcontractors - Developing appropriate metrics and audit protocols Insurance Subsidiaries - Enforcing integrity downstream - Re-insurance costs if provided by subsidiaries - Subsidiary service pricing and cost allocations

50 Beneficiary and Prescriber FWA New populations and schemes may require enhanced system edits - Addressing Issues common within the Medicaid population Development of Beneficiary and Prescriber Fraud, Monitoring, Investigation and Referral Unit - Divining whether Grandma Smith or her nephew Billy is responsible for the rash of inhaler purchases - Physician submission of claim for same drug dispensed at retail pharmacy or by infusion provider

51 Beneficiary and Prescriber FWA Physician Auditing: Identified from review of automated or ad hoc PBM Rx Utilization and Prescriber Utilization Reports Focused on identification of: - High volume prescribing of specific high dollar or abuse type of medications - Volume based tracking (number of claims, total drug spend, targeted drugs) - Review of controlled substance prescribing patterns - Cross check of patients to eliminate critically ill patients Summary reports to PBM or Part D plan sponsor for further review

52 Beneficiary and Prescriber FWA Beneficiary Auditing: Identified from automated PBM Reports or desk/on- site audits Focused review of individual patient RX utilization focusing on: - Zip code analysis of where RXs are picked up - Potential for Grey Market – second hand selling of drugs with or without the beneficiaries knowledge - Multiple pharmacy utilization for the same RX - Multiple physician visits to generate same RX

53 Retiree Drug Subsidy FWA Employer or Union Plan Sponsors are accountable for accuracy and completeness of all information submitted to CMS Application includes attestation that plan sponsor is submitting a claim to the government May delegate major data submission to CMS to subcontractors, but still accountable Oversight of subcontractors, including PBMs, is critical While Attestations are sufficient for payment, ultimately all data must be tracked to the individual retiree level by employer benefit option Timeline – Final reconciliation 15 months after the end of the plan year Prevention of errors and omissions essential through monitoring and audits

54 Retiree Drug Subsidy FWA CMS and OIG have announced that RDS audits will be a priority MEDICs tasked to review - Actuarial Equivalence – documentation to support attestation that Plan Sponsor coverage is equivalent to Part D - Accuracy of RDS Payments – review actual claims and rebate data to support RDS payment requests - Creditable Coverage Disclosures – review to assure consistent with Medicare requirements OIG: 2005 OIG workplan includes audits of CMS controls and 2006 audits will focus on AE, payments and CC notices

55 Retiree Drug Subsidy FWA Touch Points Actuarial Equivalence Attestations Supporting documentation for the gross and net tests Benefit combination assumptions for net test Assumptions on integrated medical and drug premiums Subsidy Claims and Rebate Data Controls and monitoring to assure that only claims for eligible costs are submitted, e.g. no Part B or excluded drugs Controls and monitoring to assure that complete and accurate rebate data is submitted Controls to assure no administrative costs are submitted

56 Retiree Drug Subsidy FWA Touch Points Retiree Lists Controls and monitoring to assure that only validated retirees and dependents are submitted Cross checks with CMS eligibility data Creditable Coverage Notifications Controls to assure that active workers and retirees get notices Documentation to support claims that coverage is creditable for each benefit option Controls to assure that notices for non-creditable coverage were issued

57 What Does the Future Hold?

58 Part D: Key Implementation Dates DATEIMPLEMENTATION ACTIVITY August 2005SSA begins sending decisions to those who applied for low-income subsidies; continue to accept applications September 14, 2005 CMS approves bids for PDPs and MA-PDs and formularies September 15, 2005 PDP and MA-PD contracts signed September 15 – October 15, 2005 CMS completes auto-enrollment of dual-eligibles in PDP basic plans September 16 – November 15, 2005 Medigap issuers send written disclosures to policyholders with drug coverage informing them of their options October 1, 2005Approved Part D plans begin marketing October 1, 2005Deadline for transfer of Medicare appeals from SSA to DHHS October 13, 2005CMS begins distributing information to beneficiaries comparing available Part D coverage via the Medicare & You handbook mailing, MEDICARE, and Plan Comparison web-tool and Medicare Personal Plan Finder October 15, 2005Deadline for Secretary to notify states of their annual per capita drug payment amounts (Clawback) for 2006

59 Part D: Key Implementation Dates DATEIMPLEMENTATION ACTIVITY October 27 – November 10, 2005 CMS mails auto-enrollment information to dual eligibles November 15, 2005 – May 15, 2006 Coordinated election period for 2006 Part D enrollment for all beneficiaries Medicare Part A/ B beneficiaries eligible to enroll in Medicare Part D plan of their choice November 15, 2005 – May 15, 2006 States and entities offering drug coverage provide written disclosure to Part D eligible individuals regarding actuarial equivalence December 31, 2005Last Day of Medicaid drug coverage for full benefit dual eligibles December 31, 2005Medicare drug discount card program ends for Part D enrollees (May 15, 2006 for all others) January 1, Part D coverage begins for all beneficiaries enrolled in a plan - Dual eligibles' auto-enrollment takes effect - Low-income subsidies for Part D coverage begin - Medigap insurers prohibited from selling new policies with drug coverage

60 The Politics of the MMA 2005 budget reconciliation will likely include $12B in Medicare savings: Elimination of Stabilization Fund for Regional PPOs. Codify budget neutrality policy for risk adjustment Outstanding MedPAC recommendation to reduce MA county benchmarks to 100% FFS, but no consensus on Hill to advance. Program appears stable for foreseeable future. Impact of Medicaid reform: Greater flexibility to states Emphasis on Aged/Blind/Disabled into managed care. Underscores positioning for SNPs – one-stop shopping

61 2007 Strategic Considerations Part D sponsors will be facing contraction of aggregate reinsurance Part D sponsors will be ratcheting-up control mechanisms Step therapy, prior authorization, quantity limits, strict formularies Will evidence-based practices dictate preferred drugs or tier placement in a therapeutic class?

62 Immunizing for FWA Conduct Operations GAP Analysis Part D and RDS Operations Analysis Compliance Program Review and Assessment Review PBM Operations for FWA Exposure Monitoring and audit mechanisms and staffing Performance metrics – Internal and External Reports Policies and procedures assessment and review Systems tests Contract requirements Management Oversight

63 Immunizing for FWA Ongoing FWA Program Development Business Process Workflow Documentation Policy and Procedure Development Internal Audit Procedures and Policies Subcontractor oversight program development Data Analysis to detect beneficiary, prescriber, pharmacy FWA Staff and Subcontractor training System logic review for benefit adjudication Sales program FWA monitoring program development

64 New Marketplace Expanded role of private plans – growing influence of PBMs, and of Medicare regulators on them. Increased information for plans, patients – and government. Eventual price (rebate) transparency comparative drug information increased emphasis on medical evidence and outcomes Growing pressure on price and performance. PDP competition and premium pressures pay-for-performance for providers cost-effectiveness for drugs Expanding out of pocket costs for beneficiaries Increased competition Dozens of PDPs – all majors will play increased incentives for generic substitution

65 The Challenges Moving purchasers toward value-based purchasing Better data on outcomes and quality Pay for performance -- quality indicators Integrating disease management and MTMP Plan influence on provider decision-making Proving the market works Helping the PDPs and MA-PDs survive Encouraging accelerated movement toward integrated health plans Minimizing government intervention, reference-based pricing/price controls, PDP failure Helping CMS become a successful purchaser (rather than a regulator)

66 How to Reach Us Gorman Health Group, LLC (202)

Download ppt "The Emerging Market in Medicare Part D and Sponsor Compliance Strategies A Presentation to the Pharmaceutical Compliance Congress November 8, 2005 John."

Similar presentations

Ads by Google